Stephen Connelly - Equillium Chief Scientific Officer, Director

EQ Stock  USD 0.76  0.01  1.30%   

Director

Mr. Stephen Connelly, Ph.D., is Chief Scientific Officer, Director of the company. He has served as our Chief Scientific Officer since January 2018 and as a member of our board of directors since March 2017. Dr. Connelly is a cofounder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016, Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publiclyheld biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014, where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents since 2018.
Age 43
Tenure 7 years
Professional MarksMBA
Phone858 240 1200
Webhttps://www.equilliumbio.com
Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.

Stephen Connelly Latest Insider Activity

Tracking and analyzing the buying and selling activities of Stephen Connelly against Equillium stock is an integral part of due diligence when investing in Equillium. Stephen Connelly insider activity provides valuable insight into whether Equillium is net buyers or sellers over its current business cycle. Note, Equillium insiders must abide by specific rules, including filing SEC forms every time they buy or sell Equillium'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Equillium Management Efficiency

The company has Return on Asset (ROA) of (0.0944) % which means that for every 100 dollars spent on asset, it generated a loss of $0.0944. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.1952) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities.
Equillium reports 824 K of total liabilities with total debt to equity ratio (D/E) of 0.29, which may suggest the company is not taking enough advantage from financial leverage. Equillium has a current ratio of 3.9, indicating that it is in good position to pay out its debt commitments in time. Note however, debt could still be an excellent tool for Equillium to invest in growth at high rates of return.

Similar Executives

Found 2 records

DIRECTOR Age

James CassellaTrevi Therapeutics
70
Judith MDJasper Therapeutics
68
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people. Equillium (EQ) is traded on NASDAQ Exchange in USA. It is located in 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 and employs 45 people. Equillium is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Equillium Leadership Team

Elected by the shareholders, the Equillium's board of directors comprises two types of representatives: Equillium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Equillium. The board's role is to monitor Equillium's management team and ensure that shareholders' interests are well served. Equillium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Equillium's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jason Keyes, Chief Officer
PMP MBA, Senior COO
Matthew Ritter, Senior Development
Penny Tom, Principal Officer
Maple MD, Chief Officer
Krishna MD, Consultant
Daniel Bradbury, Chairman of the Board, CEO
Bruce CFA, President, CoFounder
Joel Rothman, Chief Officer
Michael Moore, Vice Communications
Stephen Connelly, Chief Scientific Officer, Director

Equillium Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Equillium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Equillium

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.

Moving against Equillium Stock

  0.65ILMN Illumina Sell-off TrendPairCorr
  0.54NAMSW NewAmsterdam Pharma TrendingPairCorr
  0.34INZY Inozyme PharmaPairCorr
  0.32ABOS Acumen PharmaceuticalsPairCorr
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Equillium Stock Analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.